TG Therapeutics, Inc.
TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), anā¦ read more
Healthcare
Biotechnology
16 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$43.14
Price+0.65%
$0.28
1Y
Price
Market Cap
$6.604b
Mid
Price/Earnings 3y Avg5y Avg
15.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+26.8%
EBITDA Margin+12.0%
Net Profit Margin+10.2%
Free Cash Flow Margin+26.8%
EBITDA Margin+12.0%
Net Profit Margin+10.2%
Free Cash Flow MarginRevenue
$700.349m
+87.3%
1y CAGR+2806.1%
3y CAGR+2090.0%
5y CAGREarnings
$461.896m
+1812.4%
1y CAGR+667.5%
3y CAGR+509.6%
5y CAGREPS
$2.86
+1746.7%
1y CAGR+639.8%
3y CAGR+491.0%
5y CAGRBook Value
$583.131m
$1.529b
Assets$945.706m
Liabilities$753.557m
DebtDebt to Assets
49.3%
1.9x
Debt to EBITDAFree Cash Flow
-$14.191m
+38.4%
1y CAGR+30.5%
3y CAGR+33.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company